AXQ Capital LP Buys Shares of 12,829 Pfizer Inc. $PFE

AXQ Capital LP purchased a new position in Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 12,829 shares of the biopharmaceutical company’s stock, valued at approximately $311,000.

A number of other institutional investors have also made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC boosted its holdings in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 388 shares during the last quarter. Citizens National Bank Trust Department raised its position in shares of Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 395 shares during the period. Able Wealth Management LLC boosted its stake in Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock worth $512,000 after acquiring an additional 413 shares during the last quarter. Trust Co of the South grew its holdings in Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after purchasing an additional 441 shares during the period. Finally, Charter Oak Capital Management LLC increased its stake in Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 444 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on PFE shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Scotiabank began coverage on Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.39.

Pfizer Stock Performance

Shares of PFE stock opened at $25.26 on Tuesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company’s fifty day simple moving average is $24.87 and its 200-day simple moving average is $24.51. The firm has a market cap of $143.61 billion, a PE ratio of 13.44, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio is 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.